Natera stands as a global leader in cell-free DNA testing, with a dedicated focus on oncology, women’s health, and organ health, aiming to integrate personalized genetic testing into standard healthcare practices. The company's competitive advantage lies in its proprietary cfDNA technology platform, which has been validated by over 100 peer-reviewed publications for its high accuracy, and its diverse team of experts from various fields. Natera's commitment to industry leadership is evident in its ISO 13485-certified and CAP-accredited laboratories, and its proactive stance against cyber crimes, ensuring a secure and innovative work environment.